MacroGenics to Participate in Upcoming Investor Conference
MacroGenics (Nasdaq: MGNX), a biopharma company specializing in monoclonal antibody-based cancer treatments, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach.
President & CEO Scott Koenig will present on June 13, 2024, at 10:00am ET. Management will also engage in one-on-one meetings. A live webcast of the presentation will be available on MacroGenics' website, with a replay accessible for 30 days post-conference.
- Participation in the prestigious Goldman Sachs conference increases MacroGenics' visibility.
- Opportunity for one-on-one meetings with potential investors could lead to new funding and partnerships.
- Webcast availability allows broader access to the presentation, enhancing investor relations.
- No new product announcements or financial updates were disclosed in the press release.
- The impact of participation in the conference on stock performance remains uncertain.
- Potential for increased expenses related to conference participation with no immediate financial return.
ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:
- Goldman Sachs 45th Annual Global Healthcare Conference (Miami Beach). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will provide a corporate presentation on Thursday, June 13, 2024, at 10:00am ET. MacroGenics’ management will also participate in one-on-one meetings.
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
FAQ
What event will MacroGenics participate in during June 2024?
When will Scott Koenig present at the Goldman Sachs Healthcare Conference?
How can I access the MacroGenics presentation from the Goldman Sachs conference?
Will MacroGenics management have individual meetings during the conference?
